U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18N4O2
Molecular Weight 298.3397
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRIBEDIL

SMILES

C(N1CCN(CC1)C2=NC=CC=N2)C3=CC=C4OCOC4=C3

InChI

InChIKey=OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2

HIDE SMILES / InChI

Molecular Formula C16H18N4O2
Molecular Weight 298.3397
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Piribedil is an antiparkinsonian agent which acts as D2 and D3 receptor agonist. In European countries and worldwide it is used as a monotherapy or in combination with dopatherapy for treatment of Parkinson's disease, cognitive impairment and obliterating arteriopathy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35462
Gene ID: 1814.0
Gene Symbol: DRD3
Target Organism: Homo sapiens (Human)
Target ID: P14416
Gene ID: 1813.0
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRIVASTAL

Approved Use

Adjunctive treatment of intermittent claudication in chronic obliterating arteriopathies of the lower limbs (in stage 2).
Palliative
TRIVASTAL

Approved Use

Adjunctive symptomatic treatment of chronic pathological cognitive and neurosensorial deficit in elderly subjects (excluding Alzheimer's disease and other dementia).
Primary
TRIVASTAL

Approved Use

Treatment of Parkinson's disease: either as monotherapy (treatment of forms with predominant tremor), or in association with dopatherapy from the outset, or secondarily, particularly in forms with tremor.
PubMed

PubMed

TitleDatePubMed
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
1975 Jan
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
1976 May
Parkinsonism by haloperidol and piribedil.
1978 Oct 31
Sleep attacks and Parkinson's disease treatment.
2000 Apr 15
Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
2000 Feb 14
Pharmacological treatment for aphasia following stroke.
2001
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
2001 Mar
Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment.
2001 Sep
DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
2002
Gateways to clinical trials.
2002 Jul-Aug
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
[The use of pronoran (piribedil) in Parkinson's disease].
2003
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
2003 Apr
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
2003 Apr
Quantitative determination of some pharmaceutical piperazine derivatives through complexation with iron(III) chloride.
2003 Aug
Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
2003 Dec
Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum.
2003 Mar 10
[Clinical and stabilometric analysis of postural instability in Parkinson's disease].
2004
Adsorptive stripping voltammetric behaviour of azomethine group in pyrimidine-containing drugs.
2004 Feb 18
Drugs in development for Parkinson's disease.
2004 Jul
End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
2005 Jul
Chemically modified carbon paste electrode for the potentiometric flow injection analysis of piribedil in pharmaceutical preparation and urine.
2005 Jul 15
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
2005 May
[The role of pronoran in the therapy of late stage of Parkinson's disease].
2006
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
2006 Dec
Restless legs syndrome: diagnosis and review of management options.
2006 Jun
Activation of D2-like receptors induces sympathetic climactic-like responses in male and female anaesthetised rats.
2006 Jun
Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension.
2006 Mar-Apr
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
2006 Nov
Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency.
2007 Jan 30
About the anti-Parkinson equivalency of levodopa and dopamine agonists.
2007 Jan-Feb
Peripheral edema and dopamine agonists in Parkinson disease.
2007 Oct
Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
2008 Aug
Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients.
2009 Sep
Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.
2010 Dec 29
Impulse control disorder and piribedil: report of 5 cases.
2010 Jan-Feb
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
2010 Nov
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
2010 Nov 12
Patents

Patents

Sample Use Guides

For the treatment of Parkinson's disease as a monotherapy, piribedil should be administered orally at 150 to 250 mg.
Route of Administration: Oral
Binding of piribedil to D2, D3 and D4 receptors was measured using [3H]spiperone as a radiolabel. Coronal sections from rat brains were cut at the level of the anterior caudate-putame. The sections were thaw-mounted on gelatin-coated glass slides. Sections were incubated for 5 min in a 50mM Tris-HCl buffer, then were incubated for 30 min at room temperature in the incubation buffer. Piribedil was tested in vitro at 5 different concentrations, from 10 uM to 1 nM.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:35:53 UTC 2023
Edited
by admin
on Wed Jul 05 22:35:53 UTC 2023
Record UNII
DO22K1PRDJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRIBEDIL
INN   MART.   MI   WHO-DD  
INN  
Official Name English
Piribedil [WHO-DD]
Common Name English
piribedil [INN]
Common Name English
EU-4200
Code English
2-(4-PIPERONYL-1-PIPERAZINYL)PYRIMIDINE
Systematic Name English
TRIVASTAL
Brand Name English
ET-495
Code English
PIRIBEDIL [MI]
Common Name English
PIRIBEDIL [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N04BC08
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
WHO-VATC QN04BC08
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
NCI_THESAURUS C66884
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
Code System Code Type Description
DRUG BANK
DB12478
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
MESH
D010891
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
RXCUI
8353
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY RxNorm
FDA UNII
DO22K1PRDJ
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
NCI_THESAURUS
C81082
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
MERCK INDEX
M8877
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
222-764-6
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
WIKIPEDIA
PIRIBEDIL
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
ChEMBL
CHEMBL1371770
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
CAS
3605-01-4
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
INN
2569
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID9045188
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
PUBCHEM
4850
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
SMS_ID
100000081665
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
DRUG CENTRAL
2202
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
EVMPD
SUB09908MIG
Created by admin on Wed Jul 05 22:35:53 UTC 2023 , Edited by admin on Wed Jul 05 22:35:53 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY